Welcome back to the Pharmaceutical News, some generic market news today so please read on...
On 19th December 2011, Amgen and Watson Pharmaceuticals announced that they are to collaborate to develop and commercialise, on a worldwide basis, a number of oncology antibody biosimilars. The firms commented that the agreement underscored a shared belief that the development and commercialisation of biosimilar products would not follow a pure brand or generic model, and would require significant expertise, infrastructure and investment.
Under the terms of the agreement, Amgen will assume primary responsibility for developing, manufacturing and initially commercialising the products. Watson will contribute up to US$400 million in co-development costs over the course of development, including the provision of development support, and will share product development risks. In addition, Watson will contribute its expertise in the commercialisation and marketing of products in highly competitive specialty and generic markets, including helping effectively manage the lifecycle of the biosimilar products. The collaboration products are expected to be sold under a joint Amgen / Watson label. Watson will initially receive royalties and sales milestones from product revenues. The two firms commented that the collaboration would not pursue biosimilars of Amgen's proprietary products.
Please click on the link to read more articles like this; Generics News
Friday, 27 January 2012
Tuesday, 10 January 2012
Pain Therapy Drugs Market Report
Pain Therapy Drugs Market
As the market evolves over the next decade current market leaders will lose patent expiry and become subject to generic competition. What’s in the pipeline and which companies and products will prosper?
Pain affects around 1.5 billion people worldwide. In most cases, pain is temporary and easily treated with commonly available analgesics. For some people, however, pain is a debilitating, chronic condition. In Europe, an estimated 20% of the population suffers from chronic pain. As the population ages, the number of people with chronic pain is increasing, particularly from conditions such as osteoarthritis. Chronic pain is also associated with cancer. An estimated 30% of all cancer patients are in pain with the proportion more than doubling among people with late-stage cancer. In recent years, drug development in pain therapy has been focused mainly on reformulations of existing therapies and alternative modes of drug delivery in order to improve the safety and efficacy of existing drug groups.
Pain affects around 1.5 billion people worldwide. In most cases, pain is temporary and easily treated with commonly available analgesics. For some people, however, pain is a debilitating, chronic condition. In Europe, an estimated 20% of the population suffers from chronic pain. As the population ages, the number of people with chronic pain is increasing, particularly from conditions such as osteoarthritis. Chronic pain is also associated with cancer. An estimated 30% of all cancer patients are in pain with the proportion more than doubling among people with late-stage cancer. In recent years, drug development in pain therapy has been focused mainly on reformulations of existing therapies and alternative modes of drug delivery in order to improve the safety and efficacy of existing drug groups.
While highly competitive, pain remains a sector of high unmet clinical need with excellent opportunities in niche markets
While the pain market is fragmented and highly competitive, it remains an area of high unmet need as current therapies are often less than effective and/or have undesirable side-effects. A number of new drugs are poised to take market share, with Palexia/Nucynta (tapentadol) widely tipped to be among the up and coming market leaders. As the market continues to evolve over the next decade, the current market leaders will lose patent expiry and become subject to generic competition and consequent price erosion. It is generally agreed that sales of novel treatments are unlikely to entirely replace the revenue lost following patent expiry of the current top five. However, there will be opportunities in underserved niche market segments, particularly neuropathic pain, which typically fails to respond adequately to conventional analgesics.
To read more about this report, and to find out what questions it will answer, please click on the link to the Pain Therapy Drugs Market
Subscribe to:
Posts (Atom)